• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.221.1-221.1
• /
• 2000

• Biomolecules & Therapeutics
• /
• v.28 no.3
• /
• pp.222-229
• /
• 2020

The process of drug discovery and drug development consumes billions of dollars to bring a new drug to the market. Drug development is time consuming and sometimes, the failure rates are high. Thus, the pharmaceutical industry is looking for a better option for new drug discovery. Drug repositioning is a good alternative technology that has demonstrated many advantages over de novo drug development, the most important one being shorter drug development timelines. In the last two decades, drug repositioning has made tremendous impact on drug development technologies. In this review, we focus on the recent advances in drug repositioning technologies and discuss the repositioned drugs used for inflammatory diseases such as sepsis, asthma, and atopic dermatitis.

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.295.2-295.2
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2001.04a
• /
• pp.242.1-242.1
• /
• 2001

• Biomolecules & Therapeutics
• /
• v.22 no.4
• /
• pp.267-274
• /
• 2014

Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the United States Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and experimentally manageable in vivo animal models. Since the 1980's, scientists have been able to genetically modify the mouse genome by removing or replacing a specific gene, which has improved the identification and validation of target genes of interest. Now genetically engineered mouse models (GEMMs) are widely used and have proved to be a powerful tool in drug discovery processes. This review particularly covers recent fascinating technologies for drug discovery and preclinical trials, targeted transgenesis and RNAi mouse, including application and combination of inducible system. Improvements in technologies and the development of new GEMMs are expected to guide future applications of these models to drug discovery and preclinical trials.

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.304.2-305
• /
• 2001

• Proceedings of the Korean Society of Life Science Conference
• /
• 2007.10a
• /
• pp.78.2-78.2
• /
• 2007

See Full Text

• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.116.3-117
• /
• 2000

• Bulletin of the Korean Chemical Society
• /
• v.29 no.10
• /
• pp.1977-1982
• /
• 2008

Novel bicyclo[3.1.0]hexanyl purine nucleoside analogues were synthesized as potential antiherpetic agents via a bicyclo[3.1.0]hexanol (${\pm}$)-8, which was prepared using a highly efficient carbenoid cycloaddition reaction. A highly diastereoselective reduction of ketone and a Mitsunobu reaction for the condensation of glycosyl donor (${\pm}$)-12 with 6-chloropurine were employed.

• Bulletin of the Korean Chemical Society
• /
• v.29 no.12
• /
• pp.2487-2490
• /
• 2008